Roche’s entrectinib hits the mark in paediatric cancers

03:10 EDT 17 May 2019 | pharmaphorum

Roche’s entrectinib for gene fusion-positive cancers has shown promising results in a range of paediatric cancers in an early-stage trial, earning it a spotlight position at a pre-ASCO press conference. The phase 1/2 study of the in children with ...

Original Article: Roche’s entrectinib hits the mark in paediatric cancers


More From BioPortfolio on "Roche’s entrectinib hits the mark in paediatric cancers"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...